Full-Time

Digital CX Lead

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$149k - $198k/yr

+ Incentives

Toronto, ON, Canada

In Person

Bachelor's

Category
Growth & Marketing (1)

Get referred to Takeda

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Business, Marketing, Technology, Life Sciences, or related field.
  • 7+ years of relevant experience in digital engagement, omnichannel, customer experience, content management, marketing technology, or CRM/technology roles within pharmaceutical/life sciences.
  • Strong growth mindset, with openness to feedback, continuous learning, and adapting quickly in a changing business and technology environment.
  • Deep understanding of customer engagement capabilities, content management approaches, digital channels, and MarTech platforms, including platform integration and interoperability across the CX and web ecosystem.
  • Experience enabling adoption and effective use of digital and content platforms in a local market context, including campaign enablement, user training, and technical troubleshooting.
  • Experience working across business and technology organizations, with strong stakeholder management and communication skills.
  • Knowledge of data privacy, consent management, and compliance requirements in a regulated environment, including awareness of local market content requirements such as PAAB and how to partner effectively to address them.
  • Customer-focused and outcome-oriented.
  • Strong collaborator and relationship builder.
  • Drives adoption and continuous improvement.
  • Promotes knowledge sharing and best practices. Demonstrates curiosity for emerging digital and AI-enabled capabilities.
Responsibilities
  • Drive adoption of customer engagement and omnichannel capabilities across Commercial and Medical, including TakedaConnect and key web ecosystem touchpoints.
  • Support local adoption of NBA and Voice of Customer capabilities in close collaboration with DD&T team members (e.g. Tech and AI partner, data product manager) and cross-functional business partners.
  • Enable effective utilization of digital engagement platforms and services, with strong focus on understanding MarTech platform integration dependencies, interoperability needs, and reliable local execution.
  • Ensure content and campaign execution is designed to generate structured, usable data for insights, reporting, and optimization, and partner with Data Excellence and Data Products to support interoperability, consistency, and analytics readiness across CX platforms.
  • Systematically capture pain points, unmet needs, and capability gaps in Canada’s Digital CX and content ecosystem. Translate findings into clear, actionable inputs for IBU / Global DD&T platform and product teams, including assessment/activation of new channels, e.g. WABA.
  • Partner with business teams to improve customer engagement outcomes.
  • Drive adoption of Content Factory capabilities and services.
  • Enable use of Content Hub, AssembleIQ, and modular content approaches, while understanding local content requirements such as PAAB and partnering with cross-functional team and external stakeholders as needed to address them effectively.
  • Promote content reuse and content best practices.
  • Monitor adoption and identify opportunities to improve value realization.
  • Support adoption of AI-enabled customer engagement capabilities and emerging solutions.
  • Identify opportunities to improve customer engagement and content effectiveness.
  • Share successful practices and lessons learned across teams and markets.
  • Gather user feedback and recommend capability improvements, using the shared requirements-discovery approach to frame CX and content needs clearly and routing broader cross-domain demand through the Technology & AI Partner as appropriate.
  • Partner with Commercial, Medical, MCE, and DD&T teams to enable integrated customer engagement, content excellence, TakedaConnect, and the local web ecosystem.
  • Support rollout and adoption of new capabilities and enhancements.
  • Provide market feedback and local insights to global teams.
  • This role ensures local enablement, adoption, and continuous improvement of customer engagement and content capabilities in Canada, including TakedaConnect and relevant web ecosystem touchpoints, in close coordination with Technology and AI partner and other stakeholders. The role partners closely with IBU DD&T, MCE, Commercial and Marketing Operations, NGCE, and cross-functional partners in Commercial and Medical team who are responsible for content and execution within their domains.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ORZEYFUL approvals in China, the United States, and Japan create a near-term revenue engine.
  • Takeda said July 30, 2026, Q1 FY2026 results stayed on plan despite mix pressure.
  • Rusfertide and zasocitinib launches in 2026-2027 extend growth beyond mature products.

What critics are saying

  • A Massachusetts jury imposed an $885 million Amitiza antitrust verdict on May 18, 2026.
  • Takeda booked about $1 billion in FY2026 losses from restructuring and legal charges.
  • The 4,500-role 2026 cut signals deep internal strain and risks destabilizing launch execution.

What makes Takeda unique

  • Takeda owns ORZEYFUL, first oral OX2R agonist for narcolepsy type 1, approved August 2026.
  • Its Japan-originated science and global commercialization engine spans China, Japan, and the United States.
  • Takeda pairs R&D scale with broad launch execution across late-stage assets and specialty pharmacies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.

Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.

Yahoo Finance
Jul 30th, 2026
Takeda Pharmaceutical Q1 results on track as new launches offset mature product declines

Takeda Pharmaceutical reported first-quarter fiscal 2026 results aligned with its full-year outlook. Revenue totalled JPY 1.22 trillion, up 10.2% on an actual foreign-exchange basis but down 0.5% at constant exchange rates. Core operating profit reached JPY 358.9 billion, rising 11.5% on an actual FX basis. The company's core inline brands, representing 58% of total revenue, grew 2.3% at constant exchange rates. New launches accounted for 4% of revenue but grew 22.6%, supported by FRUZAQLA, LIVTENCITY, ADZYNMA and QDENGA. Takeda is preparing three product launches: ORZEYFUL for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis. The company maintained its fiscal 2026 guidance and expects to generate JPY 650 billion to JPY 750 billion in free cash flow.

Nikkei Asia
Jul 21st, 2026
India approves first dengue vaccine from Japan's Takeda

India has approved Takeda Pharmaceutical's dengue vaccine, marking the country's first approved vaccine for the disease. The Japanese drugmaker received regulatory approval as authorities seek to combat dengue's accelerating transmission across India. Dengue, a mosquito-borne viral infection, poses a significant public health challenge in tropical regions. The approval represents a milestone in India's efforts to address the disease burden. The vaccine's introduction comes as dengue cases continue to rise in the country, making prevention efforts increasingly urgent for Indian health authorities.